Evolution of the Average Target: Quest Diagnostics Incorporated

Evolution of the Target Price: Quest Diagnostics Incorporated

Changes in Analyst Recommendations: Quest Diagnostics Incorporated

8055726215dfb36504450.9Lubw7TfVQcgu8bVQTLZ_r-KLoZPtrErx5x4dFlLG3k.h_mos_3mLz9Q35adK22PneX_Z7co98lHjsgKOgkaQxrZ-qjy44dhNHbk_g~faa8b575ae694925a6c32f7d22096e93
07-28 JPMorgan Adjusts Price Target on Quest Diagnostics to $250 From $220, Maintains Neutral Rating MT
07-27 Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating MT
07-24 UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating MT
07-24 Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating MT
07-24 Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating MT
07-24 Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating MT
07-24 Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating MT
07-24 Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating MT
07-24 Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating MT
07-23 Evercore ISI Cuts Quest Diagnostics Price Target to $240 From $225 MT
07-15 Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating MT
05-18 Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating MT
04-27 Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $233 From $224, Maintains Buy Rating MT
04-22 UBS Adjusts Quest Diagnostics Price Target to $220 From $210, Maintains Neutral Rating MT
04-22 Truist Lifts Price Target on Quest Diagnostics to $225 From $220, Keeps Hold Rating MT
04-22 Evercore ISI Adjusts Price Target on Quest Diagnostics to $225 From $210, Maintains In Line Rating MT
04-22 Jefferies Adjusts Price Target on Quest Diagnostics to $225 From $220, Maintains Buy Rating MT
04-22 Barclays Adjusts Price Target on Quest Diagnostics to $230 From $225, Maintains Overweight Rating MT
04-22 Baird Adjusts Price Target on Quest Diagnostics to $229 From $224, Maintains Neutral Rating MT
04-21 Evercore ISI Adjusts Danaher Price Target to $225 From $210, Maintains Outperform Rating MT
04-21 Jefferies Raises Quest Diagnostics Price Target to $225 From $220 MT
04-21 Leerink Partners Adjusts Price Target on Quest Diagnostics to $240 From $235, Maintains Outperform Rating MT
04-14 Baird Adjusts Price Target on Quest Diagnostics to $224 From $219, Maintains Neutral Rating MT
04-08 Evercore ISI Adjusts Price Target on Quest Diagnostics to $210 From $220, Maintains In Line Rating MT
03-10 Argus Adjusts Price Target on Quest Diagnostics to $225 From $210, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.73%
+2.61%
+8.28%
+23.04%
+5.65%
+13.15%
-12.9%
+39.07%
+1.18%
+6.13%
Average +8.89%
Weighted average by Cap. +7.10%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
235.94USD
Average target price
242.38USD
Spread / Average Target
+2.73%
High Price Target
265.00USD
Spread / Highest target
+12.32%
Low Price Target
204.00USD
Spread / Lowest Target
-13.54%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JPMorgan Chase
Rothschild & Co Redburn
UBS
Baird
Barclays
Mizuho Securities
Deutsche Bank Securities
Truist Securities
Morgan Stanley
Evercore ISI
Leerink Partners
Jefferies & Co.
Argus
Piper Sandler
Citigroup
Nephron Research
Redburn Atlantic
BofA Securities
Baptista Research
Wells Fargo Securities
Credit Suisse
KeyBanc Capital Markets
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
235.94USD
Average target price
242.38USD
Spread / Average Target
+2.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DGX Stock
  4. Consensus Quest Diagnostics Incorporated